YOKOHAMA, Japan--(BUSINESS WIRE)--ReproCELL (JASDAQ:4978) announced that it has commenced operation of “Cell Innovation Partners, L.P.” (hereafter “the Fund”) at the size of about USD 8.0 million, as of September 26, 2014
Studies in pluripotent cells, including iPS cells, and in regenerative medicine have recently been accelerating in universities and research institutions worldwide; the issue now is financing the funds for development to apply the outcomes from studies in regenerative medicine. The Fund aims to contribute to the early practical application of the next generation of drug discovery and health care businesses by providing growth funds to cellular and regenerative medicine bio-venture companies inside and outside of Japan.
Help employers find you! Check out all the jobs and post your resume.
